Ibsan75 mg

Ibsan is an angiotensin II receptor blocker (ARB) with the following evidence-based indications:

• Hypertension (established/FDA-approved): Treatment of essential hypertension, alone or in combination with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
• Diabetic nephropathy (established/FDA-approved, guideline-supported): Treatment of nephropathy in patients with type 2 diabetes and hypertension, as part of an antihypertensive regimen, to reduce the rate of progression of nephropathy as measured by the doubling of serum creatinine or the occurrence of end-stage renal disease (need for dialysis or renal transplantation).
• Combination therapy: Ibsan is frequently combined with a thiazide diuretic (e.g., hydrochlorothiazide) when blood pressure is not adequately controlled on monotherapy.

Ibsan is not indicated, and must not be used, during pregnancy (see Contraindications and Pregnancy and Lactation).

Each tablet of Irbesartan contains irbesartan as the active pharmaceutical ingredient, commonly available in strengths of 75 mg, 150 mg, and 300 mg, along with standard pharmaceutical excipients (diluents, binders, disintegrants, and lubricants). Fixed-dose combination products containing Irbesartan with hydrochlorothiazide are also available.

Ibsan is a selective angiotensin II receptor blocker (ARB) belonging to the biphenyl-tetrazole group of ARBs. It is used mainly for the management of hypertension and for renal protection in patients with type 2 diabetes and hypertension. Ibsan is generally well tolerated and, unlike ACE inhibitors, is associated with a low incidence of dry cough, making it a useful alternative for patients who cannot tolerate an ACE inhibitor.

Ibsan is administered orally and does not require dose adjustment based on food intake.

Ibsan belongs to the angiotensin II receptor blocker (ARB) class of antihypertensive agents, also known as angiotensin receptor antagonists or "sartans."

Irbesartan is a potent, orally active, selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking the binding of angiotensin II to the AT1 receptor, Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to a reduction in blood pressure and to renal hemodynamic effects that help slow progression of diabetic nephropathy. Unlike ACE inhibitors, Irbesartan does not affect the metabolism of bradykinin, which accounts for its lower incidence of dry cough.

Irbesartan is well absorbed orally (absolute bioavailability approximately 60-80%), with peak plasma concentration reached in 1.5-2 hours. It is highly protein bound (~90%), metabolized in the liver primarily via glucuronide conjugation and CYP2C9-mediated oxidation, and has an elimination half-life of 11-15 hours, supporting once-daily dosing. It is eliminated mainly via the biliary and renal routes.

Ibsan is administered orally as a tablet, once daily, with or without food. Tablets should be swallowed whole with water. If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next dose, in which case the missed dose should be skipped; do not double the dose.

• Potassium-sparing diuretics, potassium supplements, and salt substitutes containing potassium: Concurrent use with Ibsan may increase serum potassium and lead to clinically significant hyperkalemia; monitor serum potassium if co-administration is necessary.
• NSAIDs (including selective COX-2 inhibitors): May reduce the antihypertensive effect of Ibsan and, in volume-depleted patients (including the elderly), may worsen renal function, including possible acute renal failure; renal function should be monitored with concurrent use.
• Lithium: Ibsan, like other agents affecting the renin-angiotensin system, can increase serum lithium concentrations and lithium toxicity risk; monitor lithium levels closely during concurrent use.
• Aliskiren: Combination of Ibsan with aliskiren is contraindicated in patients with diabetes due to increased risk of hyperkalemia, hypotension, and renal impairment, and is not recommended in patients with renal impairment (see Contraindications).
• Other antihypertensive agents and drugs that lower blood pressure (e.g., diuretics): May have an additive hypotensive effect when combined with Ibsan; dose adjustment and blood pressure monitoring may be needed.
• Dual blockade of the renin-angiotensin system (with an ACE inhibitor or another ARB): Generally not recommended, as it increases the risk of hypotension, hyperkalemia, and changes in renal function compared with monotherapy.

Ibsan is generally well tolerated. Reported side effects include:

• Common: Dizziness, fatigue, and diarrhea.
• Less common: Hypotension (particularly in volume-depleted patients), hyperkalemia (especially with renal impairment, diabetes, or concomitant potassium-elevating drugs), musculoskeletal pain, and mild elevations in creatine kinase.
• Rare: Angioedema, hypersensitivity reactions, and impaired renal function (particularly in patients dependent on the renin-angiotensin system, such as those with renal artery stenosis).

A notable, favorable feature of Ibsan, as with other ARBs, is a substantially lower incidence of persistent dry cough compared with ACE inhibitors, since it does not affect bradykinin metabolism.

Pregnancy - Contraindicated (Fetal Toxicity Warning)

Ibsan acts directly on the renin-angiotensin system and can cause injury or death to the developing fetus when used during the second and third trimesters of pregnancy, including oligohydramnios, fetal lung hypoplasia, skeletal deformations, and neonatal renal failure. Use of Ibsan during any trimester of pregnancy is contraindicated. If pregnancy is detected, Ibsan should be discontinued as soon as possible, and the patient should be switched to an alternative antihypertensive agent considered appropriate in pregnancy under medical supervision.

Lactation

It is not known whether Ibsan is excreted in human breast milk. Because of the potential for adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Ibsan, taking into account the importance of the drug to the mother; consult a physician before use while breastfeeding.

Fetal Toxicity (Boxed Warning-Level Risk)

Ibsan can cause fetal harm, including injury and death, when used during pregnancy. Female patients of reproductive potential should be counseled about this risk, and Ibsan must be discontinued as soon as pregnancy is detected (see Contraindications and Pregnancy and Lactation).

Hypotension in Volume- or Salt-Depleted Patients

Symptomatic hypotension may occur, particularly after the first dose, in patients who are volume- or salt-depleted (e.g., from high-dose diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting). This condition should be corrected prior to starting Ibsan, or a lower starting dose should be used.

Hyperkalemia

As with other drugs affecting the renin-angiotensin system, hyperkalemia can occur with Ibsan, particularly in patients with renal impairment, diabetes mellitus, or those taking potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes; periodic monitoring of serum potassium is advised in at-risk patients.

Renal Impairment / Renal Artery Stenosis

In patients whose renal function depends on the activity of the renin-angiotensin system (e.g., severe congestive heart failure or renal artery stenosis), treatment with agents that inhibit this system, including Ibsan, may be associated with oliguria, azotemia, or acute renal failure; monitor renal function during treatment.

The most likely manifestations of Ibsan overdose are hypotension and tachycardia; bradycardia may also occur from parasympathetic (vagal) stimulation. If symptomatic hypotension occurs, supportive treatment should be instituted. Ibsan is not removed by hemodialysis. If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away; do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Ibsan in children under 6 years of age have not been established. Data on antihypertensive use in children 6-16 years of age are limited, and Ibsan should be used in this age group only under specialist pediatric guidance, with the fetal toxicity risk kept in mind for adolescent females of reproductive potential.

Elderly (Geriatric) Use

No overall differences in effectiveness were observed between elderly and younger patients treated with Ibsan; a lower starting dose (e.g., 75 mg) may be considered in patients over 75 years of age or those who are volume-depleted, given a somewhat greater blood-pressure response in the elderly.

Renal Impairment

No initial dose adjustment of Ibsan is required in patients with mild-to-moderate renal impairment. Caution and monitoring of renal function and serum potassium are advised in patients with severe renal impairment or those on hemodialysis.

Hepatic Impairment

No dose adjustment of Ibsan is required in patients with mild hepatic impairment; data are limited in more severe hepatic impairment, and caution is advised.

Ibsan is typically used long-term for chronic conditions such as hypertension and diabetic nephropathy, with periodic reassessment of blood pressure, renal function, and serum potassium by the prescribing physician. Treatment should not be stopped abruptly without medical advice, and duration is determined by the physician based on ongoing clinical response and tolerability.

Irbesartan is classified as an angiotensin II receptor blocker (ARB), a class of antihypertensive agents also referred to as angiotensin receptor antagonists.

Irbesartan selectively and competitively blocks the binding of angiotensin II to the AT1 receptor subtype found in vascular smooth muscle and the adrenal gland, without activating the receptor. This blocks the vasoconstriction and aldosterone-release effects of angiotensin II, resulting in vasodilation, reduced peripheral vascular resistance, and lower blood pressure, along with favorable renal hemodynamic effects that slow progression of diabetic nephropathy.

Category D (FDA legacy classification for the second and third trimesters; contraindicated in all trimesters of pregnancy due to established risk of fetal toxicity)

The safety and efficacy of Ibsan have not been established in children under 6 years of age. Limited data exist for antihypertensive use in children 6-16 years of age, and Ibsan is not generally used as a first-line agent in this population. Any use in pediatric patients should be individualized and supervised by a pediatric specialist, and adolescent females of reproductive potential must be counseled about the fetal toxicity risk should pregnancy occur (see Pregnancy and Lactation).